Companies / MoonLake Immunotherapeutics
MoonLake Immunotherapeutics
Nasdaq: MLTXForeign · IFRSCIK 1821586ZUG
Financials
Ownership
85.1M shares outstanding · as of Aug 1, 2026
Ownership
| 10%+ / strategic | 5.12% | 4,355,433 |
| Institutions | 62.03% | 52,790,452 |
| Public float | 32.85% | 27,960,800 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 13
View all →| Insider | % of shares | Shares |
|---|---|---|
Biotechnology Value Fund II LPFormerDirector · 10% owner | — | — |
Biotechnology Value Fund L PFormerDirector · 10% owner | — | — |
Biotechnology Value Trading Fund OS LPFormerDirector | — | — |
Bodenstedt MatthiasChief Financial Officer | — | — |
Bvf Gp Holdings LLCFormerDirector · 10% owner | — | — |
Bvf I Gp LLCFormerDirector · 10% owner | — | — |
Bvf II Gp LLCFormerDirector · 10% owner | — | — |
Bvf INC/ILFormerDirector · 10% owner | — | — |
Bvf Partners L P/ILFormerDirector · 10% owner | — | — |
BVF Partners OS Ltd.FormerDirector | — | — |
Institutional holders 142
View all →| Holder | Value | % of shares |
|---|---|---|
| $298.26M | 18.80% | |
| $64.30M | 4.06% | |
| $60.76M | 5.42% | |
| $57.40M | 5.12% | |
| $44.56M | 2.81% | |
| $31.84M | 2.01% | |
| $23.07M | 2.06% | |
| $22.17M | 1.98% | |
| $21.32M | 1.29% | |
| $20.92M | 1.32% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Bvf Partners L P/IL Director | Sell | Class A Ordinary Shares, $0.0001 par value | $32.44M | -1.9M -18.88% | 8,302,735 9.76% of shares | high |
| Mar 31, 2026 | Bvf Partners L P/IL Director | Sell | Class A Ordinary Shares, $0.0001 par value | $26.35M | -1.6M -19.21% | 6,599,722 7.75% of shares | high |
| Mar 31, 2026 | Bvf Partners L P/IL Director | Sell | Class A Ordinary Shares, $0.0001 par value | $4.17M | -249K -19.30% | 1,039,238 1.22% of shares | medium |
| Jan 7, 2026 | Bodenstedt Matthias Executive | Grant | Class A ordinary shares, par value $0.0001 per share | $0 | +354K +38.43% | 1,276,305 1.50% of shares | low |
| Jun 17, 2026 | Bvf Partners L P/IL Director | Grant | Option to Buy | — | +22K | 22,195 0.03% of shares | low |
| Jan 7, 2026 | Santos da Silva Jorge CEO | Grant | Stock Option (Right to Buy) | — | +520K | 520,342 0.61% of shares | low |
| Jan 7, 2026 | Reich Kristian Executive | Grant | Stock Option (Right to Buy) | — | +520K | 520,342 0.61% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Cormorant Asset Management, LP | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| MLTX | Common Stock | 61559X104 |